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Objective: In the 2003 Supplement for tumor, node, metastasis
(TNM) Staging classification it states that TNM staging “applies to
all types of carcinoma including small cell carcinoma; however, it
does not apply to carcinoids.” Despite this caveat, most publications
on typical and atypical carcinoids use the TNM staging system for
nonsmall cell carcinoma and are able to demonstrate prognostic
significance for the different stages. For this reason, as the next TNM
Staging proposal is being considered, we sought to investigate the
carcinoid cases submitted to the International Association for the Study
of Lung Cancer (IASLC) database, as well as the National Cancer
Institute Surveillance Epidemiology and End Results (SEER).
Materials and Methods: In the data collected for the IASLC
Staging Project database over the time period 1990 to 2000, there
were 513 broncho-pulmonary carcinoids. A total of 1619 broncho-
pulmonary carcinoid cases diagnosed over the period 1990–2002
were analyzed from the SEER database, including 1437 surgical
cases. Pathologic slides were not available for histologic review.
Results: Most of tumors in both the IASLC and SEER databases
were Stage I (82% and 78%, respectively), as defined by the IASLC
proposals for the 7th edition of TNM staging system. T status was
a statistically significant predictor of survival for both the SEER data
(p  0.0001) and the IASLC database (p  0.0156), though for
different reasons. N status showed significant survival correlations
in both data sets (p  0.0001). The effect of M status was
significant (p  0.0001) within the SEER data and not studied in
the IASLC cases, which were almost exclusively M0. We found
that all three T, N, and M categories as defined for non-small cell
lung cancer are generally useful for staging of pulmonary carci-
noid tumors. Significant differences in survival for overall stages
I versus II versus III/IV were identified in both data sets. Patients
with multiple same lobe nodules had a 100% 5-year survival,
which may be a reason to reevaluate their status in the IIB
category in future analyses.
Conclusions: In summary, the IASLC proposals for the 7th edition
of TNM are helpful in predicting prognosis for broncho-pulmonary
carcinoid tumors. It is the recommendation of the IASLC Staging
project that TNM be applied to broncho-pulmonary carcinoid tu-
mors. A prospective collection of data through an International
Registry of Pulmonary Neuroendocrine Tumors planned by the
IASLC will allow for further detailed analysis of staging data for
broncho-pulmonary carcinoids.
Key Words: Carcinoid, Typical carcinoid, Atypical carcinoid,
Stage, Lung, TNM, UICC, AJCC, Survival.
(J Thorac Oncol. 2008;3: 1213–1223)
The International Association for the Study of Lung Cancer(IASLC) has sponsored a project since 1998 to formulate
proposals for revision of the tumor, node, metastasis (TNM)
staging system.1 A database of 100,869 lung cancer cases was
collected for this project. Data were accepted from all parts of
the globe, for all modalities of care, including best supportive
care, enrolled between 1990 and 2000.
Based on a statistical analysis of these cases, a series of
papers have recently been published with proposals for mod-
ifications in the T, N, and M categories as well as the resultant
stage groupings.2–6 These papers contain a series of proposals
for modifications to the current 6th Edition of the TNM
Classification of Malignant Tumors. Throughout this paper,
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we refer to these new proposals as “proposed IASLC” stage and
have classified cases according to this proposed system, unless
otherwise noted. Although carcinoid tumors were not specifi-
cally requested, data on over 500 pulmonary carcinoid tumors
were submitted to Cancer Research And Biostatistics for anal-
ysis. This led us to consider how these cases could be analyzed
in the context of the IASLC Lung Cancer Staging Project.
In the 3rd Edition of their TNM Supplement: A Com-
mentary on Uniform Use, published in 2003, the International
Union Against Cancer (UICC) state that TNM staging “ap-
plies to all types of carcinoma including small cell carcinoma;
however it does not apply to carcinoids.”7 Despite this caveat,
most publications on typical and atypical carcinoids use the
TNM staging system for nonsmall cell carcinoma and are
able to demonstrate prognostic significance for the different
stages.8–16 For this reason, as the next TNM Staging proposal
is being considered, we sought to investigate the National
Cancer Institute Surveillance Epidemiology and End Results
(SEER) registry, as well as the cases submitted to the IASLC
database,1to determine whether the current and the proposed
TNM staging systems are suitable for predicting outcome in
broncho-pulmonary carcinoids.
METHODS
IASLC Proposals for the 7th Edition of the
UICC and AJCC TNM Staging Classification for
Lung Cancer
The derivation model for the proposed IASLC Staging
system used in this manuscript has been reported in a series
of prior publications and is being considered for the upcom-
ing 7th edition of the UICC and AJCC staging system.2–6
SEER Database
Over the period 1990–2002, the SEER database had
1619 total cases with complete TNM staging and carcinoid
(ICDO-3 codes 8240 and 8249/3) as the first neoplasm. This
included 947 (58%) SEER cases between 1990 and 1997 and
672 during 1998 and through 2002. The 1437 surgically
managed cases from this cohort were chosen as a validation
group for findings based on the IASLC data. The distribution
of these cases according to the proposed IASLC pathologic
stage groupings is summarized in Table 1.
Histologic distinction between typical versus atypical
carcinoid was not generally made in the SEER data for this
time period; however, cause of death was documented. Clin-
ical stage was not reported due to lack of information regard-
ing typical versus atypical carcinoid and concerns that the
data might be contaminated by cases of large cell neuroen-
docrine carcinoma or small cell carcinoma.
IASLC Database
In the data collected for the IASLC Staging Project data-
base over the time period between 1990 and 2000, there were
513 carcinoids. The contributors for the cases, summarized in
Table 2, were predominantly surgical centers. Sufficient patho-
logic TNM data were available for 392 surgically managed
carcinoid cases. The distribution of these cases according to
pathologic stage groupings is summarized in Table 3. Clinical
stage was not evaluated because of the smaller numbers of cases
with clinical stage data. Information specifying typical versus
atypical carcinoid was only available in half of the cases. Data
on cause of death were not available in the IASLC database.
Tumor Size
Tumor size histograms were generated to compare the
distributions of tumor size for carcinoid N0 cases versus non-
small cell lung cancer (NSCLC) N0 cases, taking into account
IASLC T-category. More complete analyses of the NSCLC
cases from these databases are published elsewhere.2,5 Tumor-
lets, i.e., neuroendocrine proliferations measuring less than 0.5
cm, were by definition excluded from analyses of carcinoid
cases.
TABLE 1. IASLC Proposed Staging for Seer Carcinoid
Database by Overall Stage, Tm-Descriptor and N; Surgically
Managed Cases Only
N-Category
Total Total N0 N1 N2 N3 NX
1437 1243 124 56 4 10
IA Total stage 1A 814 814
T1a T1a: 2 cm 566 566
T1b T1b: 2–3 m 248 248
IB Total stage 1B 314 314
T2a T2a: 5 cm 314 314
IIA Total stage IIA 126 31 95
T1a T1a: 2 m 27 27
T1b T1b: 2–3 cm 23 23
T2a T2a: 5 cm 45 45
T2b T2b: 5–7 cm 31 31
IIB Total stage IIB 42 39 3
T2b T2b: 5–7 cm 3 3
T3 T3: 7 cm 7 7
T3 by invasion 19 19
T3 by same-lobe nodules 13 13
IIIA Total stage IIIA 84 15 23 46
T1a T1a: 2 cm 7 7
T1b T1b: 2–3 cm 10 10
T2a T2a: 5 cm 19 19
T2b T2b: 5–7 cm 6 6
T3 T3: 7 cm 2 2 0
T3 by invasion 10 9 1
T3 by same-lobe nodules 5 2 3
T4 T4 by same-side nodules 9 7 2
T4 by extension 16 8 8
IIIB Total stage IIIB 8 4 4
T1b T1b: 2 m 2 2
T4 T4 by same-side nodules 2 1 1
T4 by extension 4 3 1
IV Total stage IV 49 30 3 6 0 10
M1a Contralateral nodules 9 4 0 2 0 3
Malignant pleural effusion 18 9 2 1 0 6
M1b Distant metastasis 22 17 1 3 0 1
IASLC, International Association for the Study of Lung Cancer.
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Survival Analysis
Survival was measured from the date of diagnosis for
the SEER data, and from the date of surgery for the IASLC
data. Survival was estimated using the Cox regression
method. Prognostic groups were assessed by Cox regression
analysis, using the SAS system for Windows version 9.0
PHREG method. Significance values from pairwise compar-
isons reflect the Wald test; those from joint model effects
(e.g., comparing the full model to the null model) reflect the
likelihood ratio test. Significance values were not adjusted for
multiple comparisons. Survival curves were compared by T
and N status in M0 patients and by M status according to the
proposed IASLC Staging system. Survival was also analyzed
by tumor size.
Survival differences among the overall proposed
stage groupings were modeled by Cox regression, with
adjustment for gender (male versus female) and age
(greater than 60 years versus 60 or younger). The percent
variation explained by this model was approximated using
the R2 statistic.17
Because of the indolent clinical course of many carci-
noid tumors, and the available information about cause of
death in the SEER database, we made further analyses of
cancer specific survival. Here, survival was characterized in
terms of cumulative incidence of death by the carcinoid
tumor, so as to allow adjustment for the competing risk of
death due to other or unknown causes.
RESULTS
SEER Database
Clinical Features
In the SEER dataset, there were 1619 total cases with
1063 females (66%) and 556 males (34%). There were 1437
surgical cases, the focus of this analysis, with 949 females
(66%) and 488 males (34%). The median and mean age for
the surgically managed subset was 59 and 55 years (range,
12–91 years). Sixty percent were followed 5 years or until
death; and 26% were followed 10 years or until death.
Tumor Size
In the SEER surgical cases, the median and mean size
for tumors regardless of nodal status was 2 and 2.4 cm,
(range, 0.5–16.5 cm). Among the 1194 N0 cases, the peak
range for tumor size was 1.0 to 1.5 cm (Figure 1A). There
were relatively few carcinoid tumors larger than 3.0 cm
compared with NSCLC (Figure 1B).
pT, N, and M Status
The overall stages for the surgically managed SEER
carcinoid cases by TM descriptor and N are summarized in
Table 1. The SEER database documents only “best” stage–
generally, a pathologic stage if tissue was obtained, otherwise
clinical–but for these surgically managed cases, findings
were assumed to be based on the resection attempt. Stage I
TABLE 2. IASLC Staging Project Carcinoid Database, Types of Stage Data Available
Submitting Group
Clinical
TNM
Pathologic
TNM
Clinical and
Path TNM
Insufficient for
Proposed System
Clinical centre of Serbia 0 1 2 0
Guangdong provincial people’s hospital 0 4 0 2
Faculty hospital Plzen 0 0 6 0
Flemish lung cancer registry-VRGT 6 5 4 22
Grenoble university hospital-isere cancer registry 6 0 0 21
Intergroupe Francophone de Cancerologie
Thoracique (IFCT)
0 0 0 1
Japanese joint committee of lung cancer registry 2 15 54 2
John Hopkins University 4 6 29 3
Leuven lung cancer group 4 1 2 7
MD Anderson Cancer Center-Thoracic and
Cardiovascular Surgery (MDACC-TCVS)
1 5 3 8
Memorial Sloan-Kettering Cancer Center 0 9 27 1
Cancer registry of Norway 0 108 0 2
Prince Charles hospital, Brisbane 0 6 8 1
Queensland Radium Institute 10 0 0 8
St Vincent’s Hospital, Victoria 1 0 1 0
University of Sydney 1 80 0 3
Taiwan lung cancer society 0 0 3 2
Institute of lung diseases, Warsaw 0 0 13 0
Western Hospital, Melbourne 1 0 0 2
Total 36 240 152 85
Sufficient path TNM 392
IASLC, International Association for the Study of Lung Cancer; TNM, tumor, node, metastasis; IFCT, Intergroupe
Francophone de Cancerologie Thoracique.
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tumors represented 1128 of the 1437 tumors (78%); the
majority of tumors were stage IA: 57% with 39% in T1a and
17% in T1b. Stage II tumors comprised 168 (12%) of the
tumors with 9% in Stage IIA and 3% in Stage IIB. The
majority of the Stage IIA cases were T2a and T2b. Most of
the IIB tumors were T3 for reasons other than tumor size.
Stage III tumors represented 92 (6%) of all cases with 6% in
IIIA and 1% in IIIB. The largest group in stage IIIA was
T2a (1%). Stage IV represented 3% of all tumors.
Survival Analysis
For surgical cases in the SEER database, increasing T,
N, and M status generally showed correlations with reduc-
tions in survival (Figures 2A–C). Survival for T3 was signif-
icantly different from T1 to T2 (p  0.0001); however, there
was little difference in survival between T1 and T2 in this
dataset. For T status, with any N category, T1a/T1b had the
same 5-year estimated survival at 93/92% and T2a/T2b had
the same survival at 90% (Figure 2A). T3 with size greater
than 7 cm had a slightly worse survival at 65% compared
with 79% assigned to T3 because of same lobe nodules and
74% assigned to T3 because of other descriptors (Figure 2A).
There were significant differences (p  0.0001) in survival
by N status in M0 cases, with 5-year survival estimates
reduced from 92% for N0 to 81% for N1, 74% for N2 and 0%
for N3 (Figure 2B). Survival for M0 cases was significantly
different from M1 (p  0.0001), with 5-year survival of
57% for M1 compared with 91% for M0 cases (Figure 2C).
In surgically treated M1 cases (data not shown), there were
no deaths in 7 cases with contralateral nodules nor in the
11 T4 cases with same-side nodules and only 2 deaths in
the 18 T3 cases with same-lobe nodules (79% 5-year
survival).
When applying the IASLC TNM proposal for the 7th
Edition to pathologic stage cases, Stage 1A/1B contained
814/314 cases, respectively, and 5-year survival was similar
at 91 to 93% (Figure 3A). The numbers of cases were much
smaller for IIA/IIB with 126/42 cases for proposed IASLC,
respectively. The 5-year estimated survival for IIA/IIB cases
in the proposed IASLC staging system was similar (85/86%).
For Stage IIIA/B and IV, there were 84/8 and 49 cases,
respectively, using the proposed IASLC staging system. Sur-
vival for IIIB (47%) was worse than both IIIA (78%) and
stage IV (57%). For the combined stage groups survival for
Stage 1 was 93%, for Stage II it was 85%, for Stage III it was
75% and for Stage IV it was 57% (Figure 3B).
Table 4 summarizes the results of Cox proportional
hazards regression applied to the SEER data, modeling sur-
vival differences between the main overall stage groups (I
versus II versus III versus IV) with adjustment for age and
sex. In this model, stage II was significantly different from
stage I (hazard ratio  1.98, p  0.0012), and stage III was
significantly different from stage II (hazard ratio  2.25, p 
0.0028), but stage IV and III were not significantly different
(hazard ratio  1.19, p  0.5656). Older age greater than 60
years compared with 60 years or less (hazard ratio  3.75,
p  0.0001) and male sex (hazard ratio  1.40, p  0.0291)
significantly correlated with worse survival.
Cancer Specific Survival, SEER Database
There were 195 deaths in the 1437 surgically managed
SEER patients (13.6%), but only 56 of these deaths were
specifically attributed to the primary lung tumor. In our
analysis of the cumulative incidence of death due to carcinoid
with adjustment for competing risk of death due to other or
unknown causes, the 5-year estimates for all stages for the
IASLC proposal showed substantially less mortality (Figure
4) compared with Kaplan Meier survival analysis using death
for any cause (Figures 3A, B). In general, these curves
showed increased tumor-related deaths with increasing stage.
Nevertheless, in the IASLC proposed system, there were
fewer deaths in the IIB (1 total/3% at 5 years) than the IIA
patients (11 total/7% at 5 years) (Figure 4). In addition, we
were not able to demonstrate significant differences accord-
ing to tumor size for T1N0 at 2 cm or for T2N0 at 4 or 5 cm
cutoffs (data not shown).
There were insufficient data for typical versus atyp-
ical carcinoids to make any conclusion regarding stage and
survival.
TABLE 3. IASLC Proposed Staging or IASLC Carcinoid
Database, Pathologic Stage by pTM-Descriptor and pN
pN-Category
Total Total N0 N1 N2
392 350 29 13
IA Total stage 1A 267 267
T1a T1a: 2 cm 154 154
T1b T1b: 2–3cm 72 72
T1x T1x, no size 41 41
IB Total stage 1B 56 56
T2a T2a: 5 cm 56 56
IIA Total stage IIA 37 10 27
T1a T1a: 2 cm 8 8
T1b T1b: 2–3 cm 8 8
T1x T1x, no size 1 1
T2a T2a: 5 cm 10 10
T2b T2b: 5–7 cm 10 10
IIB Total stage IIB 18 17 1
T2b T2b: 5–7 cm 1 1
T3 T3: 7 cm 1 1
T3 by invasion 9 9
T3 by same-lobe
nodules
7 7
IIIA Total stage IIIA 13 0 1 12
T1a T1a: 2 cm 2 2
T1b T1b: 2–3 cm 1 1
T2a T2a: 5 cm 5 5
T2b T2b: 5–7 cm 1 1
T3 T3: 7 cm 1 1 0
T3 by invasion 3 0 3
IV Total stage IV 1 0 0 1
M1b Distant metastasis 1 0 0 1
IASLC, International Association for the Study of Lung Cancer.
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IASLC Database
Clinical Features
There were a total of 513 carcinoids in the IASLC
database. The median and mean age for all tumors was 58 and
54 years (range, 13–88 years). There were 269 females
(55%), 216 males (45%), and 28 with no gender data.
For the IASLC surgical database, 75%were followed 5 years
or until death; and 29%, were followed 10 years or until death.
Tumor Size
In the IASLC database the pathologically measured tumor
size, regardless of nodal status, was a median and mean of 2.0
and 2.3 cm (range, 0.5–8.5 cm). In the IASLC database, the
peak range for T1a carcinoid tumors was1.5 to 2.0 cm. There
were relatively few tumors larger than 3.0 cm compared with
NSCLC (data not shown).
pT, N, and M Status
The pathologic stage, by pTM descriptor and pN for the
IASLC carcinoid database is summarized in Table 3. Stage I
tumors represented 323 of the 392 tumors (82%); the majority of
tumors were stage IA: 68% with 39% in T1a, 18% in T1b, and
unknown tumor size in 10%. Stage II tumors comprised 55
(14%) of the tumors with 9% in Stage IIA and 5% in Stage IIB.
Most of the IIB tumors were T3 for reasons other than tumor
size; 17 were N0 and only one was N1 including 7 cases that
were T3 by multiple nodules and showed 100% 5-year survival.
Stage III tumors represented 13 (3%) of all cases, all of them in
IIIA. There was only one Stage IV case (1%) by distant
metastases.
Survival Analysis
Survival by T and N status generally showed reduc-
tions in survival with increasing category. Pairs of adjacent
pT subcategories were not formally compared due to the
small numbers of cases, however, the overall effect of pT
status on survival was significant (p  0.0156) There were
no deaths in the seven cases designated T3 by reason of
same-lobe additional nodules.
The effect of pN status on survival was significant
(p  0.0001); there was a reduction in survival from pN0
cases to pN1 and pN2 cases that was more apparent at 10
years (84%, 54%, and 0%) than at 5 years (92%, 68%, and
64%), respectively. Overall, there was a significant differ-
ence in survival for the majority pN0 versus pN1 (p 
0.0006), but not between the less populated groups of pN2
versus pN1.
Analyzing the data according to the proposed IASLC
pathologic stage, Stage 1A/1B contained 267/56 cases
respectively and 5-year survival was similar at 93 to 94%
FIGURE 1. Histograms of tumor size, SEER
surgically treated cases diagnosed 1990–2002.
A, Carcinoid (n  1194); tumor size by pro-
posed IASLC T-category, N0 cases only. B,
Non-small Cell Lung Carcinoma (NSCLC) data-
base (n  23,780); tumor size by proposed
IASLC T-category, N0 cases only.
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(data not shown). Five-year survival for IIA/IIB was 74%/
83%, but there were only 37/18 cases respectively. Five-
year survival for IIIA was 67%, and there were no IIIB
cases. With only one Stage IV case, survival was not
assessed.
Table 5 summarizes the results of Cox proportional haz-
ards regression applied to the IASLC data, modeling survival
differences between the main overall pathologic stage groups
represented in the data, with adjustment for age and sex. In this
model, stage II was significantly different from stage I
(hazard ratio  2.94, p  0.0005), and stage III (exclu-
sively IIIA) was significantly different from stage II (haz-
ard ratio 5.15, p 0.0001). Older age greater than 60 years
compared with 60 years or less (hazard ratio  8.85, p 
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FIGURE 2. SEER surgically treated carcinoid
cases diagnosed 1900–2002, death by any
cause. A, T1–T3 by size and proposed IASLC
T-category, any N. B, Survival by N-category
in M0 cases. C, survival by IASLC proposed
M-category.
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0.0001) significantly correlated with worse survival but male sex
did not and the effect of being male bordered on significance
(hazard ratio  1.69, p  0.0557).
For the T1N0 carcinoids, there was significantly worse
survival (p  0.0077) for those with tumors 2 to 3 cm
(88%) compared with 2 cm (94%).
There were insufficient data for typical versus atyp-
ical carcinoids to make any conclusion regarding stage and
survival.
DISCUSSION
We found that all T, N, andM categories as defined by the
IASLC proposal for the 7th Edition of the NSCLC TNM staging
system are generally useful for staging of broncho-pulmonary
carcinoid tumors. While the subcategories of the stage groupings
for (IA versus IB and IIA versus IIB) do not show significant
differences in survival across the board in our analysis, the
combined stage categories (I versus II versus III/IV) do show
significant differences. Our findings indicate there are two major
issues that need further study in staging of broncho-pulmonary
carcinoids: (1) carcinoids presenting with multiple nodules and
(2) whether the new larger proposed size cutoffs of 5 and 7 cm
are meaningful in carcinoids.
In the SEER data base, patients with multiple nodules
had an excellent survival with no deaths in the 17 patients
with M1a contralateral nodules or T4 same side nodules (but
separate lobe to that of the primary tumor) and only 2 deaths
0%
20%
40%
60%
80%
100%
0 5 10 15
Years from diagnosis
IA
IB
IIA
IIB
IIIA
IIIB
IV
Deaths / N
89 / 814
32 / 314
23 / 126
5 / 42
22 / 84
5 / 8
19 / 49
5-Year
Estimate
93%
91%
85%
86%
78%
47%
57%
0%
20%
40%
60%
80%
100%
0 5 10 15
Years from diagnosis
I
II
III
IV
Deaths / N
121 / 1128
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FIGURE 3. SEER Surgically treated carcinoid
cases diagnosed 1900–2002, death by any
cause. A, IASLC proposed stage, all stage
groupings. B, IASLC proposed stage, combined
stage groupings.
TABLE 4. Survival Comparisons Between Proposed Stages
(I vs. II vs. III vs. IV) Within Seer Database, Surgically
Managed Cases
Comparison Hazard Ratio p
II vs. I 1.98 0.0012
III vs. II 2.25 0.0028
IV vs. III 1.19 0.5656
Age 60 vs. 60 3.75 0.0001
Male vs. female 1.40 0.0291
R²  41.3
Cox regression model adjusted for age and sex.
n  1437 (195 events).
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in 18 T3 patients with same lobe nodules. In the IASLC
database, the 7 cases with multiple same lobe nodules were in
the IIB category and they had a 100% 5-year survival.
Patients with multiple pulmonary carcinoids are likely to
have the recently recognized underlying preinvasive lesion of
diffuse idiopathic pulmonary neuroendocrine cell hyperpla-
sia.18–21 Most of these patients are women, nonsmokers and
approximately half present with one or more pulmonary
nodules that are usually discovered as an incidental finding,
while the remaining patients present with findings of inter-
stitial lung disease with features of small airways disease.
The prognosis for these patients is usually excellent,19 which
is one potential explanation for why the patients with multiple
pulmonary nodules of carcinoid tumors in both the IASLC
and SEER database had such a favorable outcome. Because
of its extremely favorable survival in both the SEER and
IASLC datasets, it is possible that the multiple nodule subset
of pulmonary carcinoids should be staged differently from
NSCLC. However, addressing this would require more detailed
data describing T factor status in a larger number of cases.
A major difference between carcinoids and NSCLC
that impacts on staging is that carcinoids are smaller. About
half the carcinoid tumors we studies were 2 cm or smaller,
whereas, the majority of NSCLC were larger than 2 cm. For
this reason, the additional tumor size splits in the proposed
IASLC staging system at 5 and 7 cm were difficult to assess.
Analysis of the IASLC database demonstrated significant
reductions in survival for pT1N0 carcinoids according to size
at 1 and 2 cm cutoffs. In the SEER database, we attempted to
perform a running log-rank test to determine the optimal size
cut offs for predicting prognosis similar to the approach by
Rami-Porta et al.5 However, the variation in individual size
measurements among SEER pT1N0 cases was greater than
our threshold for a meaningful split point, so we did not use
the running log rank analysis in this study.
Although the distinction between typical and atypical
carcinoid is a very important issue in the study of pulmonary
carcinoids, these data were unavailable in both the SEER and
the IASLC datasets for several reasons. First, the diagnostic
criteria evolved over the time period of data collection for this
study, with new criteria being adopted by the World Health
Organization in 1999.22 To achieve accurate data regarding
the classification of typical versus atypical carcinoid histo-
logic review of all pathology slides would have been re-
quired; however, for practical reasons this was not possible.
The SEER registry has not recorded data on typical versus
atypical carcinoid over the study period. Because we could
not perform pathology review for either the SEER or the
IASLC datasets analyzed in this study, we chose to analyze
all carcinoids together, realizing from the outset the limita-
tions of this approach. A potential source of bias in our data
with nodal and metastasis categories is the inextricable link to
cell type, where atypical carcinoid tumors carry a worse
prognosis. However, since some useful observations regard-
ing overall use of TNM in carcinoids resulted from these
data, we sought to report them in this manuscript.
Most of the survival analyses in this study are based on
overall survival that includes death from any cause, even if
not related to the carcinoid tumor. Because of the relatively
favorable survival of patients with carcinoid tumors com-
pared with NSCLC, particularly for typical carcinoid, the
overall survival data presented in this paper probably exag-
gerate the mortality due to carcinoids. Unfortunately, cancer
specific cause of death was not recorded in the IASLC
database and only was available in a small subset of the
SEER database. To address this issue using cancer specific
cause of death, we performed a survival analysis by all stage
groupings using cumulative incidence of death due to carci-
noid tumor; as expected, we found substantially reduced
mortality compared with the overall survival curves. To
evaluate critically TNM for staging of broncho-pulmonary
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FIGURE 4. SEER surgically treated carcinoid
cases diagnosed 1900–2002, cancer specific
cause of death, cumulative incidence of lung
cancer death, all stage groupings.
TABLE 5. Survival Comparisons Between Proposed
Pathological Stages (I vs. II vs. III) Within IASLC Carcinoid
Database
Comparison Hazard Ratio p
II vs. I 2.94 0.0005
III vs. II 5.15 0.0001
Age 60 vs. 60 8.85 0.0001
Male vs. female 1.69 0.0557
R²  52.0
Cox Regression model adjusted for age and sex.
n  372 (56 events), excluding cases with unknown age or sex.
IASLC, International Association for the Study of Lung Cancer.
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carcinoids future collection of staging data should require
cancer specific survival in addition to overall survival.
There are several limitations to this study that present
challenges to establishing TNM as applicable to pulmonary
carcinoids. Firstly, carcinoids only comprise 1 to 2% of all
resected lung malignancies so there are relatively few cases.
For this reason, it is difficult for single institutions to have
sufficient cases to publish definitive studies. Some of the
largest studies to date are from international registries9,23 or
institutions with large referral case material.15,16 Secondly, as
survival is very favorable compared with NSCLC, it is
difficult to accumulate sufficient events such as recurrence or
death to perform a rigorous statistical analysis for prognostic
factors. Another major problem is that carcinoid tumors have
historically been regarded as “benign” tumors so some cancer
registries including the SEER registry have not always cap-
tured data for these patients. While patients with typical
carcinoids have an excellent survival even if they present
with lymph node metastases,24 all carcinoids are malignant
tumors with the potential to metastasize and result in fatal
outcome.15 Finally, because the UICC/AJCC TNM staging
system has not been formally recommended for staging of
carcinoid tumors, a concerted effort has not been made to
collect detailed TNM factor status in these patients. In many
of the cases analyzed in this study, detailed T factor status
was not available, and all T factors were not captured for the
entire time period of the study. For example, SEER uses a
single variable to code extent of disease. The farthest extension
is coded, rather than all aspects of tumor extension. Also, the
“additional nodules, same lobe” code was added in 1997, so we
were not able to identify these cases if diagnosed prior to 1997.
It would be worth gathering specific data to determine if T
factors such as tumor location in the main bronchus less than 2
cm from the carina and pleural invasion in addition to tumor size
are important in staging of pulmonary carcinoids.
In summary, TNM provides an excellent way to record
the anatomic extent of disease for broncho-pulmonary carci-
noid tumors in a prognostically meaningful way. We hope
that, with recommendation by the UICC and AJCC to use
TNM for staging of broncho-pulmonary carcinoids, future
investigators will gather greater detail on TNM factors to
allow for a more thorough evaluation of staging for these
tumors. Two areas that need attention are the multicentric
carcinoid tumors arising in the setting of diffuse idiopathic
pulmonary neuroendocrine cell hyperplasia and collection of
larger number of cases to see if the proposed size cutoffs are
as applicable to carcinoids as to NSCLC. Another important
issue is to obtain disease specific survival data for both
typical and atypical carcinoids. Because of the favorable
survival in most carcinoid patients, death of unknown cause
should not be assumed to be tumor related and every effort
should be made to determine if the patient died because of
their pulmonary carcinoid tumor. The IASLC proposes to
include neuroendocrine tumors in the prospective database
planned for the next phase of the Lung Cancer Staging
Project. In this project, detailed T, N, and M factor data in
addition to cancer specific cause of death will be collected.
We expect that collection of these pivotal data will allow for
better determination of the optimal staging system for bron-
cho-pulmonary carcinoids.
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